Printer Friendly

SCICLONE PHARMACEUTICALS ANNOUNCES APPROVAL TO BEGIN CLINICAL TRIALS IN JAPAN FOR THYMOSIN ALPHA 1

 SAN MATEO, Calif., July 6 /PRNewswire/ -- SciClone Pharmaceuticals Inc. (NASDAQ: SCLN) today announced that its Japanese licensee Schering- Plough KK has received the necessary government and institutional approvals to initiate human testing of thymosin alpha 1. Approval from the U.S. FDA to export the drug for clinical trial use in Japan has also been granted, and clinical testing there will begin. Intended indications for clinical study are chronic hepatitis B and C. Hepatitis, a serious disease which can lead to cirrhosis of the liver and liver cancer, is a major problem in Japan, which has approximately 3 million hepatitis B and C carriers.
 Schering-Plough Corp. and SciClone Pharmaceuticals Inc. announced previously on Jan. 27, 1993, the signing of a long-term semi-exclusive licensing agreement under which Schering-Plough KK will undertake development, registration and marketing of thymosin alpha 1 in Japan. In return, SPKK will pay SciClone initial and milestone payments and buy bulk drug exclusively from SciClone for both clinical trial use and commercial use following marketing approval. Contingent upon successful research and development results, development costs and payments to SciClone could reach $35 million.
 Thomas E. Moore, chairman and chief executive officer of SciClone Pharmaceuticals, pointed out that the U.S. FDA approval to export thymosin alpha 1 to Japan for clinical investigation represents the fifth such country approval granted to SciClone in the last eight months.
 SciClone is primarily engaged in the acquisition, development and marketing of pharmaceuticals on a worldwide basis. The company's primary focus is on therapeutics for infectious diseases (such as hepatitis B), cancers and immune system disorders that are life- threatening and place major burden on the world's health care systems.
 -0- 7/6/93
 /CONTACT: Thomas E. Moore, chairman and chief executive officer of SciClone, 415-358-3456; or media relations, Liz Landy, or investor relations, Lilian S. Stern, 212-505-1919, both of Burns McClellan, for SciClone/
 (SCLN)


CO: SciClone Pharmaceuticals Inc.; Schering-Plough KK ST: California IN: MTC SU:

GT-TM -- SF007 -- 9068 07/07/93 12:23 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 7, 1993
Words:332
Previous Article:INTERNATIONAL YOGURT ANNOUNCES APPROVAL AS COPACKER OF PRODUCT FOR WEIGHT WATCHERS
Next Article:BELLSOUTH PROPOSES UNPRECEDENTED ACCESS TO ITS ADVANCED INTELLIGENT NETWORK
Topics:


Related Articles
THYMOSIN ALPHA 1 TO BE EVALUATED IN CLINICAL TRIAL IN MEXICO
SCICLONE PHARMACEUTICALS BEGINS ASYMPTOMATIC HEPATITIS B TRIALS IN SINGAPORE
SCICLONE RESPONDS TO ALPHA 1 PRELIMINARY TRIAL REPORT
NOVEL ACTIN-SEQUESTERING PEPTIDE TO BE DEVELOPED BY ALPHA 1 BIOMEDICALS, INC.
SIGNIFICANT RESULTS IN HEPATITIS C STUDY WITH THYMOSIN ALPHA 1 AND INTERFERON ALPHA COMBINATION THERAPY
SCICLONE PHARMACEUTICALS REPORTS CONTINUED ENCOURAGING TREND IN TAIWAN CLINICAL TRIAL AND COMPLETION OF ANALYSIS OF U.S. CLINICAL TRIAL
NEW COMBINATION DRUG THERAPY FOR CHRONIC HEPATITIS C DOUBLES SUSTAINED REMISSION OVER THOSE RATES REPORTED WITH STANDARD THERAPY
Hepatology Article Points to Promise of Thymosin Alpha 1 as a Therapy for Hepatitis C
SciClone Announces that Schering-Plough K.K. Has Advanced the Japanese Hepatitis C Program for ZADAXIN(R) Thymosin Alpha 1
SciClone's ZADAXIN(R) Thymosin Alpha 1 Decreases Formation of Lung Tumors In Mice

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters